This may not be the answer to your question, but what struck me about the article is that the possible reduction in stroke risk was mentioned only in passing at the end of the article. Why wasn’t stroke risk considered a more consequential area for investigation when the JELIS trial was designed, and why isn’t it considered a more consequential area for investigation now?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”